Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation : I-MOVECOVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Rose, Angela M.C. ; Nicolay, Nathalie ; Martín, Virginia Sandonis ; Mazagatos, Clara ; Petrović, Goranka ; Baruch, Joaquin ; Denayer, Sarah ; Seyler, Lucie ; Domegan, Lisa and Launay, Odile , et al. (2023) In Eurosurveillance 28(47).
Abstract

Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received≥14 days before symptom onset (stratifying first booster into received<150 and≥150 days after last PSV dose). We measured VE overall,... (More)

Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received≥14 days before symptom onset (stratifying first booster into received<150 and≥150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29–54) for complete PSV (with last dose received≥150 days before onset), while it was 59% (95% CI: 51–66) after addition of one booster dose. The VE was 85% (95% CI: 78–89), 70% (95% CI: 61–77) and 36% (95% CI: 17–51) for those with onset 14–59 days, 60–119 days and 120–179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset<120 days after first booster dose.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Eurosurveillance
volume
28
issue
47
article number
2300187
publisher
European Centre for Disease Prevention and Control (ECDC)
external identifiers
  • scopus:85177865991
  • pmid:37997665
ISSN
1025-496X
DOI
10.2807/1560-7917.ES.2023.28.47.2300187
project
Infectious diseases surveillance, vaccine effectiveness and determinants of acceptance
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2023 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
id
685722a5-24a9-4f3e-b57e-157060601450
date added to LUP
2024-01-16 14:29:25
date last changed
2025-02-06 04:40:27
@article{685722a5-24a9-4f3e-b57e-157060601450,
  abstract     = {{<p>Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received≥14 days before symptom onset (stratifying first booster into received&lt;150 and≥150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29–54) for complete PSV (with last dose received≥150 days before onset), while it was 59% (95% CI: 51–66) after addition of one booster dose. The VE was 85% (95% CI: 78–89), 70% (95% CI: 61–77) and 36% (95% CI: 17–51) for those with onset 14–59 days, 60–119 days and 120–179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset&lt;120 days after first booster dose.</p>}},
  author       = {{Rose, Angela M.C. and Nicolay, Nathalie and Martín, Virginia Sandonis and Mazagatos, Clara and Petrović, Goranka and Baruch, Joaquin and Denayer, Sarah and Seyler, Lucie and Domegan, Lisa and Launay, Odile and Machado, Ausenda and Burgui, Cristina and Vaikutyte, Roberta and Niessen, F. Annabel and Loghin, Isabela I. and Husa, Petr and Aouali, Nassera and Panagiotakopoulos, George and Tolksdorf, Kristin and Horváth, Judit Krisztina and Howard, Jennifer and Pozo, Francisco and Gallardo, Virtudes and Nonković, Diana and Džiugytė, Aušra and Bossuyt, Nathalie and Demuyser, Thomas and Duffy, Róisín and Nguyen, Liem Binh Luong and Kislaya, Irina and Martínez-Baz, Iván and Gefenaite, Giedre and Knol, Mirjam J. and Popescu, Corneliu and Součková, Lenka and Simon, Marc and Michelaki, Stella and Reiche, Janine and Ferenczi, Annamária and Delgado-Sanz, Concepción and Makarić, Zvjezdana Lovrić and Cauchi, John Paul and Barbezange, Cyril and Van Nedervelde, Els and O’Donnell, Joan and Durier, Christine and Guiomar, Raquel and Castilla, Jesús and Jonikaite, Indrė and Bruijning-Verhagen, Patricia C.J.L.}},
  issn         = {{1025-496X}},
  language     = {{eng}},
  month        = {{11}},
  number       = {{47}},
  publisher    = {{European Centre for Disease Prevention and Control (ECDC)}},
  series       = {{Eurosurveillance}},
  title        = {{Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation : I-MOVECOVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022}},
  url          = {{http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300187}},
  doi          = {{10.2807/1560-7917.ES.2023.28.47.2300187}},
  volume       = {{28}},
  year         = {{2023}},
}